Dan Dan Dong
Director/Miembro de la Junta en INNOCARE PHARMA LIMITED .
Perfil
Dan Dan Dong is the founder of Shanghai Rarestone Health Tech Group Co. Ltd.
She is currently an Independent Non-Executive Director at InnoCare Pharma Ltd., a Director at VISEN Pharmaceuticals (Shanghai) Co., Ltd., an Executive Director at VISEN Pharmaceuticals, and the Chief Business Officer at Arrivent BioPharma, Inc. Previously, she served as the Managing Director at Vivo Capital LLC from 2011 to 2021.
Dr. Dong completed her undergraduate degree at Sichuan University in 2006 and obtained her doctorate from Fudan University in 2011.
Cargos activos de Dan Dan Dong
Empresas | Cargo | Inicio |
---|---|---|
ARRIVENT BIOPHARMA, INC. | Corporate Officer/Principal | 01/08/2021 |
INNOCARE PHARMA LIMITED | Director/Miembro de la Junta | 11/10/2023 |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Director/Miembro de la Junta | 07/11/2018 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Director/Miembro de la Junta | 01/02/2019 |
Antiguos cargos conocidos de Dan Dan Dong.
Empresas | Cargo | Fin |
---|---|---|
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Corporate Officer/Principal | 01/07/2021 |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | Fundador | - |
Formación de Dan Dan Dong.
Sichuan University | Undergraduate Degree |
Fudan University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ARRIVENT BIOPHARMA, INC. | Health Technology |
INNOCARE PHARMA LIMITED | Health Technology |
Empresas privadas | 4 |
---|---|
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Finance |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | Health Technology |
- Bolsa de valores
- Insiders
- Dan Dan Dong